Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO has laid out his new plan, which is a lot like the old one. Start new studies, submit new ANDAs and get approvals to create a self-sustaining pipeline and grow the company. Nothing is really happening until then. We might get a little Adderall pickup, or a tiny tailwind from Loxapine launch, acquisition of Adderall rights from Mikah to increase margins, but nothing significant to drive the price north anytime soon.
It will come, but not until at least 3 years down road if management can execute. 3rd time is the charm.
What we need is an actual pipeline, revenue and profitability without the aid of PPP grants. Clear and open communication would also be great mixed with a sprinkle of no more side deals with Mikah.
Yes, it would not work to their benefit. Once they get the pipeline going that they should have done years ago they would be ready with fundamentals to uplist. Elite has been a show me stock for years. It has consistently shown that it’s in a rut, but hopefully it’s starting to dig out, but with a plastic spoon.
We spent a ton on ANDAs in the past that we just sold off for pennies on the dollar. Let’s see if Elite can prove that they can both invest and execute for heavy top line growth. Adderall ANDAs have been less than stellar after CEO hyped that they expect 10% of the market of a billion dollar market. Adderall ER is struggling to get 1% of the market.
Execution speaks louder than words, which is why this stock is stuck. Even though the company has finally reached CFP, management has to rebuild trust with investors. Lack of communication doesn’t help. Management should never surprise investors and this company is always full of surprises. I’ll let others determine whether those surprises have been good or bad surprises. Just look at stock price. Hint: Stock price is lower than when CEO started 8 years ago and dilution has tripled.
In a year revenues won’t be substantially higher and neither will the stock price. We hope to have an FDA submission at this time next year. ~3 years away from any major stock appreciation, but completely depends on ability to get through FDA timely and select good distribution partners that can penetrate markets.
Last cc addresses this. 2-3 years away from R/S and move to NASDAQ if investments pay off for FDA submissions. Is history a good guide for Elite’s future return on investment? TBD and the can is kicked down the road once again.
Nah, just wildly incorrect guesses.
Board members are voted in by shareholders. Management supports the presented board member(s). If shareholders vote to the opposite, that is a wake up call to mgmt that their vision doesn’t align with shareholders and they adjust accordingly. This is typically easier to negotiate with large investors as it requires only a few to negotiate with to get a majority. Elite is the same, Nasrat and a few insiders own close to the majority of shares and can do as they please. Shareholder vote from retail holders doesn’t hold much weight unfortunately.
Huge ask as retail holders continue to sell. No change in direction for company anytime soon.
The value is the exact same unless the price rises or tanks. Without a game plan and execution the price would simply fall and the R/S would be meaningless. I don’t think it’s happening anytime soon because the company is in a rebuilding phase for the 3rd time in 8 years.
That was before the three bucket strategy fell apart. Hype before execution is simply big talk. Execution is the hard part, which differentiates real leaders from the rest of the pack.
However, none of those uses are approved by the FDA.
In 2 years?
I’d like to see consistent revenue and pipeline growth and consistent profitability without a PPP loan forgiven. I’d like to see the CEO be paid in cash vs dilution. I’d like to see a consistent strategy executed without bailing mid-way after expending millions. Baby steps are finally being taken after 8 years, but we’re at least a few quarters away before we start getting a solid read in how the CEO is yet again positioning the company. With minuscule revenue in a billion dollar market, management needs to execute far better and select better distribution partners.
Why in the world would you do a stock split? There is already a billion shares outstanding?
The company is finally CFP, but has the dilution aftermath as if it should have millions on the coffers. Very little to show for it. The company continues to limp along another day. Hopefully we’ll see revenue start increasing after the last several quarters of declining rev. Definitely not a growth company and until they start having a pipeline that succeeds. The company is in a billion dollar Adderall market and struggling to penetrate it. That’s a major concern.
I doubt it. There’s no expectation of news other than quarterly releases and pipeline is being rebuilt. No need to check in on a daily basis since there is no news to report.
I don’t recall any comment that Mikah relationship would be kept at arms length. It wasn’t to even be in existence.
Sarcasm. We used Epic years ago and they sat on the drugs with which we partnered with them to sell and now are back in the saddle again. When one does the same thing over and over and expects different results…
Safe Harbor language protects the CEO using forward looking wording. Read the language in the script that takes place before every conference call.
We are recycling the Epic relationship. Huge win there.
Ceased with a caveat for other opportunities, per the CEO. That same CEO doesn’t have a stellar record at picking investments for which dilution is used based on the number of ANDAs that were sold off and halted by the FDA, but we did get some great winners in buying from Mikah!
8 years of being a deal maker…
Then my permissions must not let me see the right chart. I see basically a 4month chart. Going back 5-years the stock was over a dime and has consistently fallen since then. The chart I see posted tops out at 0.06.
That is clearly not a 5-year chart.
I believe Elite still has the Codeine ANDA that has been sitting unused for a few years…
Except Elite sold off all their opioid ANDAs for peanuts and SequestOx was halted by FDA years ago.
Except there are no buyers in sight. The bottom keeps falling out.
Why not? The dilutive effect is all the same regardless of board or exchange with low rev and no pipeline there is virtually little forward benefit. Generic Rx, which is all company does now and will focus on doesn’t get a multiple premium.
I believe that is a different Elite.
There is no theory in my comments. That’s what has and is happening. That’s reality.
How do Elite shareholders benefit with all the side deals Elite has done with Mikah, the CEO’s private company?
How do Elite shareholders benefit from the continual dilution for compensation to the CEO vs cash comp? Seems like base comp+options should be used instead of straight pay then this would align with shareholders more.
How do shareholders benefit from lack of company execution, while the CEO increases company ownership?
How do shareholders benefit from the low stock price vs CEO that gets paid in more shares the lower the stock price goes?
I don’t think it’s due until 45 days after the Qtr, which means the 16th. If released on the 13th, which is a Friday, don’t expect good news realistically or superstitiously.
Because that’s perfectly legal. Remember who the lawyer is here.
*incent
Options to invent them to add value and increase the share price. Much different payment structure for CEO.
He already had his first refiling of financial statements as well. Filling in Carter’s shoes quite well.
Investors aren’t seeing any value added in 8 years of management. Stock price is lower than it was when CEO first came on board. Mediocre execution couldn’t keep pace with the dilution + ongoing threat of such.
So the threat of more dilution doesn’t have an impact on the PPS along with the continual dilution of CEO pay? I think that reference would be found in the fiction section of the library.
LT retail holders bailing as we heard from Snup yesterday. 8+ years is plenty of time to turn around a company and show a good return for shareholders. ELTP BOD clearly feels differently. Going to be more of the same - waiting another “couple years”...